FAST Biomedical Invested 2011 | Exited 2022

FAST BioMedical is a privately held late clinical-stage medical technology company. The company is currently developing technology to quantify volume status and kidney function in clinically actionable time frames. This technology aims to have a significant impact on the treatment of patients with heart failure, cardio-renal syndrome, sepsis, and more. FAST BioMedical’s technology works by measuring concentrations of fluorescent in vivo markers over time. It is designed to be timely, providing volume status determinations in 45 minutes and kidney function in 210 minutes, thus allowing for timely clinical action. It is accurate, with a coefficient of variation (R-squared) of 0.9961 when FBM’s kidney function (mGFR) was compared to iohexol mGFR in a clinical study. It is convenient, needing only routine blood draws that fit into the current clinical workflow.  It does not require  urine samples,  radioactive material, or specialized handling or expensive equipment.

Holder of over 60 global patents, Carmel, IN-based FAST BioMedical has completed four clinical studies in Germany and the United States and requires only one more trial for regulatory approval in the United States and Europe.

Investigational product not approved for human use.